Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

novolimus

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Macrolides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A multicenter post‐marketing evaluation of the Elixir DESolve® Novolimus‐eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study
  • H. Nef, J. Wiebe, +10 authors C. Hamm
  • Catheterization and cardiovascular interventions…
  • 2018
    • Corpus ID: 3670644
To date, experience with bioresorbable scaffolds (BRS) that elute agents other than everolimus is limited. Thus, a post‐marketing… Expand
Review
2017
Review
2017
A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives.
The DESolve® scaffold (Elixir Medical Corporation, Sunnyvale, California, USA) is manufactured from a poly-l-lactide based… Expand
2017
2017
Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
OBJECTIVES The purpose of this study was to compare the 1-year outcome of everolimus-eluting bioresorbable scaffolds (eBRS) and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2016
Highly Cited
2016
Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
OBJECTIVES This study sought to report the late multimodality imaging and clinical outcomes of the novel poly-l-lactic-acid-based… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2016
2016
DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial.
AIMS Newer-generation drug-eluting stents (DES) have been shown to be superior to first-generation DES. Current-generation DES… Expand
Review
2016
Review
2016
Organ transplantation and drug eluting stents: Perioperative challenges
  • A. Dalal
  • World journal of transplantation
  • 2016
    • Corpus ID: 15813515
Patients listed for organ transplant frequently have severe coronary artery disease (CAD), which may be treated with drug eluting… Expand
  • table 1
  • table 2
2010
2010
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.
AIMS Novolimus, a macrocyclic lactone with anti-proliferative properties, has a similar efficacy to currently available agents… Expand
2010
2010
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.
textabstractAims: Novolimus, a macrocyclic lactone with anti-proliferative properties, has a similar efficacy to currently… Expand
2010
2010
Novolimus™-eluting coronary stent system
Owing to their marked efficacy in reducing restenosis, drug-eluting stents currently represent the predominant strategy for… Expand
  • figure 1
  • table 1
  • figure 2
2008
2008
EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions.
AIMS First generation DES have markedly reduced restenosis. However, there is a major interest in developing new DES with greater… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE